

CITELINE AWARDS 2025

ENTRY GUIDE

THURSDAY, MAY 8, 2025

DOWNTOWN BOSTON THEATER DISTRICT HOTEL | HYATT REGENCY BOSTON

ENTRY AND GENERAL INQUIRIES:

Natalia Kay

Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards



THE CITELINE AWARDS

ENTER
ATTEND
NETWORK
CELEBRATE

WHERE EXCELLENCE IN CLINICAL RESEARCH SHINES BRIGHT

Prepare to be inspired at the Citeline Awards as we celebrate the extraordinary achievements in the clinical research industry. These prestigious Awards unite visionary leaders from the biopharmaceutical, research & development, and biopharma innovation worldwide.

Now in their 9th year, the Citeline Awards, shines a spotlight on the brilliant minds, risk-takers, and strategic thinkers within global healthcare. These unsung heroes work at the cutting edge of clinical trial R&D, striving to achieve groundbreaking innovations. Be part of a celebration that champions the relentless drive to make a difference. The Awards champion individuals, teams and companies revolutionizing the industry.

This year, there are 4 brand new categories to enter!

THE 2025 CATEGORIES ARE:

1. Excellence in Rare Disease Drug Development
2. Most Successful Early Phase Research (Preclinical & Phase I)
3. Champion of Diversity & Inclusion in Clinical Research
4. Clinical Research Team of the Year – Biotech
5. Clinical Research Team of the Year – Pharma
6. Clinical Partnership of the Year – Non CRO
7. CRO Partnership of the Year **NEW**
8. Innovative Clinical Trial Design **NEW**
9. Industry Achiever **NEW**
10. Clinical Trial Result of the Year
11. Social/Community Development **NEW**

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

WHY ENTER?

**ENTER
ATTEND
NETWORK
CELEBRATE**

JOIN US IN HONORING THE PASSIONATE TRAILBLAZERS WHO DEDICATE THEIR TALENTS AND TO TRANSFORMING HUMAN LIVES

This Awards ceremony is a tribute to innovation, resilience, and the relentless pursuit of breakthroughs that redefine the future of health.

Showcase Your Achievements at the Citeline Awards!

Submit your entry for a chance to gain global recognition and access unparalleled promotional and networking opportunities:

- **Highlight** your company's innovations to a global audience
- **Connect** with key prospects, customers, and partners
- **Boost** your brand with our global marketing campaign
- **Impress** an esteemed judging panel of influential industry experts
- **Network** with top executives at the prestigious Awards ceremony on Thursday, May 8, 2025

Entry Details:

- \$99 per entry, this fee will be waived for any companies booking a full or half table, before February 21, 2025
- \$199 per entry for late submissions
- Entry fees include event attendance when booking a minimum of three seats.

Enter as many categories as you wish and put your company in the spotlight!

HOW TO ENTER:

VISIT - www.citeline.com/awards/citelineawards

CREATE - your online account

SELECT - your category or categories

COMPLETE - your online entry form(s) explaining why you or your company should be considered a winner this year. Please refer to the category criteria as a guide

SUBMIT - your entry and you will receive an automated submission receipt and an invoice will be sent to you shortly after your submission

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE



EXCELLENCE IN RARE DISEASE DRUG DEVELOPMENT

The attempt to combat rare diseases is a challenging task that exemplifies how the pharmaceutical industry addresses unmet medical needs. This Award will recognize the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases. The judges will be looking for a drug development program or trial with the largest potential impact in the rare disease space. Outstanding patient centric processes and innovation in study conduct to overcome the various obstacles of rare disease drug development will also earn high marks.

To be eligible, drug development activities must have taken place between January 2024 – February 2025. Entrants must have played a role in drug development and/or trial conduct, and all joint parties must be disclosed in the application.

“This Award will recognize the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases.”

To enter this category, please provide the following:

- The name of the individual, team, or company, including an outline of their role(s)
- Details of the drug development program or clinical trial, i.e., rare disease(s) being targeted, name of drug(s), trial name(s) (title, protocol ID, trial identifier), phase, patient segment(s) studied, and sponsor(s)
- Provide evidence of the impact that the drug has had, or potentially could have, on the patient population and addressing unmet medical needs
- Describe any unique strategies used to ensure successful study execution within this challenging space, such as trial design, patient centric processes (e.g., close engagement of patient advocacy groups), innovative patient recruitment methods in identifying potential trial participants, use of synthetic controls, or study planning strategies (i.e., use of surrogate markers or original tools and approaches to gather key clinical data)
- If available, please provide documentation in support of the achievements described

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

2

MOST SUCCESSFUL EARLY PHASE RESEARCH (PRECLINICAL & PHASE I)

This Award will recognize an early phase research project that met or surpassed its objectives on a range of key performance indicators. The entrant should show that the successful completion of the program was material in enabling the sponsor to advance its drug to the next development phase either on or ahead of schedule and/or keeping within its development budget.

To be eligible, results for the study or program under nomination must have been released between January 2024 - February 2025. Entrants must have played a role in the early phase research, and all joint parties must be disclosed in the application.

“The entrant should show that the successful completion of the program was material in enabling the sponsor to advance its drug to the next development phase either on or ahead of schedule and/or keeping within its development budget.”

To enter this category, please provide the following:

- Full details of the project; project name (i.e. name of drug candidate or trial title), phase of development, target indication and population studied (if applicable), sponsor(s), and the primary drug(s) tested
- Summarize the major findings of the study, such as in vitro/in vivo results or primary/co-primary and main secondary endpoints
- What were the main milestones and deadlines for the preclinical or Phase I study? Please supply evidence of how these were met or surpassed
- How did this study enable advancement of the drug to the next development stage?
- If available, please provide documentation of trial results; i.e. press release, investor presentation, conference abstract/presentation, clinical study report synopsis or other publication

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE



CHAMPION OF DIVERSITY AND INCLUSION IN CLINICAL TRIALS

Enhancing the diversity of clinical trial populations is critical to achieving equity in healthcare and improving health outcomes in our most vulnerable populations. Historically, clinical trial populations have been rather homogenous, and treatment effect and patient outcomes observed in a trial setting may have limited applicability to the larger 'real world' population.

This Award will recognize a company, team or individual who has demonstrated exceptional initiative in promoting diversity and inclusion of underrepresented populations within a clinical trial or drug development program. The entrant should describe the activities/strategies implemented and the impact they had on patient enrolment. Activities ranging from patient-focused study design, use of technology, awareness and recruitment campaigns, or other creative and innovative approaches will be considered. Evidence of the impact these activities/strategies had on recruitment should also be included.

“Enhancing the diversity of clinical trial populations is critical to achieving equity in healthcare and improving health outcomes in our most vulnerable populations.”

To be eligible, the initiatives undertaken must have been activated between January 2024 – February 2025. Entrants must have played a role in the design, launch or execution of the plans, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

- Full details of the project, project name (i.e., name of drug candidate or trial title), phase of development, target indication and population studied (if applicable), sponsor(s), and the primary drug(s) tested
- What specific strategies/activities were undertaken? At what point in the study were they deployed?
- Describe the impact the strategies/activities had on study recruitment. Please share any relevant metrics used for measuring impact
- If available, please provide documentation of trial recruitment campaign or any other publicly available sources that illustrate the strategies/activities undertaken

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE



CLINICAL RESEARCH TEAM OF THE YEAR – BIOTECH

(OPEN TO BIOTECH COMPANIES ONLY)

The winning biotech research team will have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

To be eligible, the core project for the nominated team must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the core project for the product.

“The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.”

To enter this category, please provide the following:

- The company’s name, the team being entered and basic details of its core project
- What was the greatest achievement of the team during the qualifying period?
- How did all members/functions of the team work together to achieve its goals?
- How does the achievement contribute to advancing new therapies to market?
- What work practices has the team adopted to support the success of the product’s development?
- If you believe that this team is particularly outstanding, but for reasons not covered in the questions above, please give relevant details

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE



CLINICAL RESEARCH TEAM OF THE YEAR – PHARMA

(OPEN TO PHARMA COMPANIES ONLY)

The winning pharma research team will have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

To be eligible, the core project for the nominated team must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the core project for the product.

“The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.”

To enter this category, please provide the following:

- The company’s name, the team being entered and basic details of its core project
- What was the greatest achievement of the team during the qualifying period?
- How did all members/functions of the team work together to achieve its goals?
- How does the achievement contribute to advancing new therapies to market?
- What work practices has the team adopted to support the success of the product’s development?
- If you believe that this team is particularly outstanding, but for reasons not covered in the questions above, please give relevant details

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

6

CLINICAL PARTNERSHIP OF THE YEAR – NON CRO

This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2024/25. Partnerships could take place between multiple pharmaceutical and/or biotech companies or between a pharmaceutical and/or biotech company and a research institute, non-profit, or cooperative group.

To be eligible, the collaborative clinical trial activity in question must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the collaborative clinical trial activity, and all joint parties must be disclosed in the application.

“This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2024/25.”

To enter this category, please provide the following:

- Provide the names of organizations involved and basic details of the partnership
- Why was the partnership novel?
- How does this partnership set a new benchmark for other deals?
- How has partnership achieved an outcome that would not have been possible if partnership had not been created?
- Please provide documentation in support of the achievements described



ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

7

CRO PARTNERSHIP OF THE YEAR

This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2024/25. Partnerships for this award must be between a pharmaceutical or biotech company and a contract research organization.

To be eligible, the collaborative clinical trial activity in question must be ongoing or completed between January 2024 - February 2025. Entrants must have played a role in the collaborative clinical trial activity, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

- Provide the names of organizations involved and basic details of the partnership
- Why was the partnership novel?
- How does this partnership set a new benchmark for other deals?
- How has partnership achieved an outcome that would not have been possible if partnership had not been created?
- Please provide documentation in support of the achievements described

“This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2024/25.”



ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

8

INNOVATIVE CLINICAL TRIAL SOLUTIONS

Clinical trials are high risk, expensive, resource-intensive undertakings that present significant challenges to any company. This award will recognize a pharma/biotech company that has developed creative and innovative approaches to the formidable challenges that clinical trials present.

Solutions may include innovations in designing any clinical trial related activity including patient recruitment and engagement or protocol design elements such as remote/decentralized trials, master protocols, complex adaptive/Bayesian trials, external controls, and other novel clinical trial designs. Solutions must have been developed or applied between January 2024 - February 2025.

Companies wishing to enter must have been involved in the clinical trial, and all parties to any joint development activities must be disclosed in the application.

“This award will recognize a pharma/biotech company that has developed creative and innovative approaches to the formidable challenges that clinical trials present.”

To enter this category, please provide the following:

- The name of the company and the innovative solution
- Specify the date of first implementation
- Outline the key features and benefits of the innovative design, and the impact it had on the study timeline, costs, or quality. Where applicable, include cost and/or time savings data to support any claims
- What problems does this innovative approach solve and what is novel about it?
- If possible, please provide additional supporting documentation (process flow chart, video, etc.)



ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

9 INDUSTRY ACHIEVER

With this award, we are looking to recognize the accomplishments of an exceptional individual with a consistent history of significant contributions to the biopharma research and development field. This award will go to someone who has had a distinguished career in R&D or clinical research, working at a pharmaceutical company, biotech or research institution. The nominee should have a history of successful projects that have had a positive impact on human health. Metrics can include scientific publications and citations; patents and involvement in innovation; involvement in clinical trials and drug approvals; contributions to the development of future scientists and leaders in the field through mentorship, training programs, and leadership roles in professional organizations.

Nominees may be retired or still working either at a pharma company, biotech or research institution.

“We are looking to recognize the accomplishments of an exceptional individual with a consistent history of significant contributions to the biopharma research and development field.”

All nominations must include:

1. The nominee's name and job title
2. The company name (if applicable)
3. If an investigator, the names of major clinical trials the nominee has been involved in
4. Your contact details
5. The contact details of the nominee

A summary of up to 750 words of why your nominee is worthy of receiving the Industry Achievement Award



ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

10

CLINICAL TRIAL RESULT OF THE YEAR (OPEN TO PHARMA & BIOTECH COMPANIES ONLY)

This Award will recognize the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare. The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

To be eligible, results for the study under nomination must have been presented in the public domain between January 2024 - February 2025. Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

“The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design.”

To enter this category, please provide the following:

- Full details of the study; i.e. trial name (title, protocol ID, trial identifier), phase, disease type and patient segment(s) studied, sponsor(s), and the primary drug(s) tested
- Summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints
- Provide evidence supporting uniqueness and advancement of knowledge in an area of unmet medical need or clinical trial design
- How do these findings represent a potential leap forward in therapy?
- Documentation of publicly available trial results required; i.e. press release, conference abstract/presentation, clinical study report synopsis or other publication

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CATEGORIES AND ENTRY CRITERIA

ENTER
ATTEND
NETWORK
CELEBRATE

11 SOCIAL/COMMUNITY DEVELOPMENT AWARD

Across the biopharmaceutical industry, companies make great efforts to support patients and communities. This Award will recognize a company's efforts to improve their community, either through work with a patient advocacy organization, a direct effort within a community, scholarship or other funding programs or other forms of social investment. These activities could involve disease education and awareness initiatives, efforts to improve patient engagement and amplify patient voices, or efforts to improve health equity through education, outreach, charity initiatives, sponsorship or direct community investment.

“This award will recognize a company’s efforts to improve their community, either through work with a patient advocacy organization, a direct effort within a community, scholarship or other funding programs or other forms of social investment.”

- The nominee(s) must be currently employed by a pharmaceutical or biotech company
- The nominee(s) should have demonstrated significant efforts in reducing patient burden, championing patient communities or causes
- The nominee(s) should describe how their actions have met the needs of a patient group or community
- Provide relevant communication/education material for judges to review



ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

JUDGED BY AN ESTEEMED PANEL OF JUDGES

ENTER
ATTEND
NETWORK
CELEBRATE

THE CITELINE AWARDS

We are proud to feature an independent judging panel of senior, globally recognized industry experts, carefully selected for their expertise, impartiality, and credibility.

How It Works

- Judges review submissions within their areas of specialization, ensuring each entry receives expert, focused attention
- Every category is evaluated by at least three judges against clear, published criteria, with scores out of ten determining the shortlist and ultimate winners
- The chair of the Judging Panel may cast a deciding vote if necessary, ensuring fair and thorough adjudication

Transparency & Confidentiality

- Shortlisted entries will be announced on our website
- Winners remain confidential until revealed at the Citeline Awards ceremony
- The judges' decisions are final, with no correspondence entered into regarding results

Showcase Your Excellence!

Visit www.citeline.com/awards/citelineawards to learn more.



ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

WHO CAN ENTER

ENTER
ATTEND
NETWORK
CELEBRATE

THE CITELINE AWARDS ARE OPEN TO ANY RESEARCH BASED PHARMACEUTICAL OR BIOTECH COMPANY

Open to any research based pharmaceutical or biotech company operating anywhere around the world, as well as to some third-party or partner companies that supply services to the pharmaceutical industry.

Entries are charged at \$99 per entry – you can enter as many relevant categories as you wish.

THE RULES

All entries must be written in English.

- Limit your entry to 1000 words or less
- All entries must be accompanied by a 100-word synopsis of the entry as you would like it to appear on all publicity material (this is in addition to the 1000 words or less entry)
- All entries must be submitted via our online system
- All entries must be based on activities undertaken between January 2024 - February 2025
- Companies may enter more than one category, provided that each entry has been specifically written to address the relevant criteria and is accompanied by a separate 100-word synopsis

CONFIDENTIALITY

- The organizer of the Citeline Awards, recognizes and respects the sensitive nature of the information submitted in the entries. We ensure that this recognition is shared by our Judging Panel. We therefore require each judge to sign a confidentiality agreement before they are appointed
- Entries are not disclosed or discussed outside the judging process
- Once an entry is shortlisted, extracts from the entry summary only will be sourced for inclusion in the Awards ceremony and any subsequent editorial coverage
- Please ensure your entry summary contains no confidential or sensitive information. The Judging Panel for each Award is selected to avoid any conflict of interest

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

FAQ's

**ENTER
ATTEND
NETWORK
CELEBRATE**

Q: How do I enter?

A: It's easy!

1. Read the entry guidelines and category criteria.
2. Choose the categories you wish to enter.
3. Create an account on our entry system, where you can save and edit your entries until submission.
4. Answer the category-specific questions and criteria.
5. Once ready, click Submit!

You can review and edit your entries up to the submission deadline Friday, February 21, 2025.

Q: How much does it cost to enter?

A:

- \$99 per entry, this fee will be waived for any companies booking a full or half table, February 21, 2025
- \$199 per entry for late submissions

Entry fees include event attendance when booking a minimum of three seats.

Fee Terms:

- Each entry incurs a fee
- 1 entry fee is redeemable per three seats booked
- A maximum of three entry fees can be applied toward a table of 10 seats
- Fees cannot be combined across different entrants
- Invoices for fees will be issued after the entry deadline

Q: When is the entry deadline?

A: Friday, February 21, 2025.

Q: What if I'm unsure about the right category?

A: Contact Natalia Kay at natalia.kay@citeline.com for guidance.

Q: Can I submit entries into multiple categories?

A: Yes! Submitting to multiple categories is encouraged. Tailor your entry to each category's criteria. Each entry is charged separately at \$99.

Q: I am a sponsor of the Awards. Can I still enter?

A: Absolutely! Sponsors are welcome to enter any category—except the one they are sponsoring. Your entry will be submitted to the independent judging panel in the same way as all other entries.

Q: How will I know my submission has been received?

A: You'll receive an automated confirmation email once your entry is submitted. Additionally, our Awards team will follow up after the entry deadline. For concerns, contact Natalia Kay at natalia.kay@citeline.com.

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

FAQ's

ENTER
ATTEND
NETWORK
CELEBRATE

Q: How will I know if my submission is successful?

A: All entrants will be notified via email after judging. Finalists will also be announced on our website: www.citeline.com/awards/citelineawards.

Q: What do winners receive?

A: Winning a Citeline Award is a prestigious honor, recognizing you as an industry leader. Winners will be announced at the Citeline Awards ceremony on Thursday, May 8, 2025 at the Downtown Boston Theater District Hotel | Hyatt Regency Boston, and will receive:

- A trophy
- Certificate of recognition
- Social media banners

Q: How can I ensure I attend the networking ceremony?

A: Secure your spot at this exclusive event by booking your place. For more information, contact George Wilkins at george.wilkins@norstella.com.

Q: Are there other ways to get involved in the Awards?

A: Yes! We offer various sponsorship opportunities. For details, reach out to George Wilkins at the email above. Ready to showcase your achievements? Get started today! www.citeline.com/awards/citelineawards.

HOW TO ENTER

VISIT - www.citeline.com/awards/citelineawards

CREATE - your online account

SELECT - your category or categories

COMPLETE - your online entry form(s) explaining why you or your company should be considered a winner this year. Please refer to the category criteria as a guide

SUBMIT - your entry and you will receive an automated submission receipt and an invoice will be sent to you shortly after your submission

ENTRY AND GENERAL INQUIRIES:

Natalia Kay • Email: natalia.kay@citeline.com

www.citeline.com/awards/citelineawards

CITELINE AWARDS 2025

THURSDAY, MAY 8, 2025

DOWNTOWN BOSTON THEATER DISTRICT HOTEL | HYATT REGENCY BOSTON

ENTRY AND GENERAL INQUIRIES

Natalia Kay, Global Events Director

Email: natalia.kay@citeline.com

SPONSORSHIP AND ATTENDANCE INQUIRIES

George Wilkins, Sales Manager

Email: george.wilkins@norstella.com

www.citeline.com/awards/citelineawards

 **CITELINE**